vancomycin has been researched along with sparfloxacin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Cui, L; Hiramatsu, K; Neoh, HM; Shoji, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 1 |
| Cars, O; Löwdin, E; Odenholt-Tornqvist, I | 1 |
| Cagni, A; Chuard, C; Lew, DP; Schrenzel, J; Vaudaux, PE | 1 |
| Carbon, C; Cochereau, I; Marrakchi-Benjaafar, S; Pocidalo, JJ | 1 |
| Cooper, B; Freeman, C; Mazens-Sullivan, M; Nightingale, C; Quintiliani, R; Robinson, A | 1 |
| Appelbaum, PC; Jacobs, MR; Pankuch, GA | 1 |
| Herrera-Insúa, I; Jacques-Palaz, K; Murray, BE; Rakita, RM | 1 |
| Hoban, DJ; Karlowsky, JA; Zhanel, GG | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Blandino, G; Caccamo, F; Milazzo, I; Musumeci, R; Nicoletti, G; Speciale, A | 1 |
16 other study(ies) available for vancomycin and sparfloxacin
| Article | Year |
|---|---|
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Chromosome Walking; DNA-Binding Proteins; Genetic Engineering; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Quinolones; Streptococcus pneumoniae; Vancomycin; Virginiamycin | 1992 |
Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Quinolones; Roxithromycin; Streptococcus pneumoniae; Streptococcus pyogenes; Vancomycin | 1992 |
Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Foreign Bodies; Guinea Pigs; Methicillin Resistance; Microbial Sensitivity Tests; Quinolones; Rats; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1995 |
Systemic prophylaxis of experimental staphylococcal endophthalmitis: comparative efficacy of sparfloxacin, pefloxacin, imipenem, vancomycin, and amikacin.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Eye; Eye Infections, Bacterial; Female; Fluoroquinolones; Imipenem; Pefloxacin; Quinolones; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1995 |
In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Depsipeptides; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Fusidic Acid; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Novobiocin; Peptides, Cyclic; Quinolones; Teicoplanin; Vancomycin; Virginiamycin | 1995 |
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
Topics: Anti-Infective Agents; Ciprofloxacin; Erythromycin; Fluoroquinolones; Kinetics; Microbial Sensitivity Tests; Penicillin G; Quinolones; Streptococcus pneumoniae; Time Factors; Vancomycin; Virginiamycin | 1994 |
Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Enterococcus faecium; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Neutrophils; Quinolones; Vancomycin; Virginiamycin | 1996 |
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
Topics: Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Ceftriaxone; Cephalosporins; Ciprofloxacin; Clindamycin; Clostridium; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Imipenem; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma; Quinolines; Streptococcus; Teicoplanin; Thienamycins; Vancomycin | 2002 |